EcoDrugPlus

Cytochrome P450 3a40

Ensembl ID : ENSSLDG00000022618
Gene Symbol: LOC111663301
3 Cross references
551 Possible Orthologues:

Cytochrome P450 Family 19 Subfamily A Member 1

Ensembl ID : ENSSLDG00000021152
Gene Symbol: CYP19A1
4 Cross references
244 Possible Orthologues:

Delta-Type Opioid Receptor-Like

Ensembl ID : ENSSLDG00000014528
Gene Symbol: LOC111663732
3 Cross references
214 Possible Orthologues:

Delta-Type Opioid Receptor-Like

Ensembl ID : ENSSLDG00000015731
Gene Symbol: LOC111656999
3 Cross references
197 Possible Orthologues:

Delta-Type Opioid Receptor-Like

Ensembl ID : ENSSLDG00000020031
Gene Symbol: LOC111660061
3 Cross references
191 Possible Orthologues:

Diacylglycerol O-Acyltransferase 1-Like

Ensembl ID : ENSSLDG00000011104
Gene Symbol: LOC111662381
3 Cross references
190 Possible Orthologues:

Diacylglycerol O-Acyltransferase 1-Like

Ensembl ID : ENSSLDG00000016981
Gene Symbol: LOC111652724
3 Cross references
189 Possible Orthologues:

Dihydroorotate Dehydrogenase (Quinone)

Ensembl ID : ENSSLDG00000021516
Gene Symbol: DHODH
3 Cross references
172 Possible Orthologues:

Dihydropyridine-Sensitive L-Type Skeletal Muscle Calcium Channel Subunit Alpha-1-Like

Ensembl ID : ENSSLDG00000006563
Gene Symbol: LOC111668912
3 Cross references
198 Possible Orthologues:

Dihydropyridine-Sensitive L-Type Skeletal Muscle Calcium Channel Subunit Alpha-1-Like

Ensembl ID : ENSSLDG00000020286
Gene Symbol: LOC111668619
3 Cross references
195 Possible Orthologues:

Dihydropyrimidine Dehydrogenase

Ensembl ID : ENSSLDG00000007009
Gene Symbol: DPYD
3 Cross references
211 Possible Orthologues:

Discoidin Domain Receptor Tyrosine Kinase 2

Ensembl ID : ENSSLDG00000019977
Gene Symbol: DDR2
3 Cross references
190 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).